Table of Contents
Published: May 1, 2026
Read Time: 3.8 Mins
Total Views: 132
The Cochrane Collaboration published an analysis last month of seven monoclonal antibody drugs developed to clear amyloid-beta from the brains of patients with Alzheimer’s disease, and the conclusion was clinically devastating. After reviewing 17 randomized controlled trials involving more than 20,000 patients, the reviewers found that the benefit of these drugs, on cognitive function, on dementia severity, and on the ability of patients to manage daily life, was at best trivial after 18 months of treatment. The drugs also raised the risk of brain swelling and bleeding, side effects that in most patients produced no symptoms but that should not be dismissed as cost-free.
The amyloid hypothesis, the idea that dementia is caused by the buildup of amyloid-beta protein in the brain, has driven billions of dollars in pharmaceutical investment over decades, and the recent FDA approvals of two anti-amyloid drugs were treated in some quarters as a vindication of that long bet. The Cochrane review suggests the vindication may have been premature.
The Trivial-Benefit Problem in Drug Approval
Some Alzheimer’s specialists have pushed back on the methodology, with one critic comparing the review to mixing rotten ingredients with fresh food and declaring the meal inedible. The objection has merit as a methodological point, since lumping failed compounds together with the two most recently approved drugs can mask a real signal in the better products. The trial results for those two recently approved drugs showed only modest slowing of cognitive decline, which means patients still got worse, just less quickly than they would have without the drug. Whether patients or their families can perceive that difference in daily life is genuinely unclear, and as one Cochrane author put it, the benefit was far below the minimal effect that a patient or caregiver would notice at all.
This is the gap between statistical significance and clinical significance, and it is one of the most underappreciated problems in pharmaceutical regulation. A drug can clear an FDA approval threshold based on a measurable effect, an effect statistically distinguishable from placebo, while remaining too small to matter to anyone living with the disease. Patients pay tens of thousands of dollars a year for these therapies; insurers, including Medicare, are absorbing those costs at scale; and the underlying clinical question, whether the patient or the family can tell the drug is working, often goes unanswered.
Aging Without Better Tools
One of the genuine successes of modern public health is that Americans are living longer, and longevity is increasing across most of the world. That success has not been matched by progress in preventing or managing the conditions of aging that now define late life for tens of millions of people. The Cochrane review is a reminder that even the best available pharmacological therapies for one of the most common and most feared age-related diseases are not, at present, worth using for most patients.
It is also a reminder that consumers and clinicians need to be skeptical, not credulous, about claims that a new therapy works. The same scrutiny applies to the longevity industry’s expanding catalogue of supplements, diagnostics, and interventions, where the gap between what is being sold and what the evidence supports is often wider than the gap in Alzheimer’s drug approvals. Asking what the evidence shows, what it suggests, and what remains uncertain is not a hostile act toward science. It is the practice of science.
The right response to a disappointing Cochrane review is not to give up on Alzheimer’s research; it is to demand that the next generation of trials be designed to measure outcomes that matter to patients and families, and that approval thresholds reflect those measures. A drug that clears amyloid from the brain without producing a perceptible benefit in daily life is a biomarker success and a clinical failure. Continuing to treat the first as evidence of the second is how we got here.
